1999
Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy
Shevitz A, Knox T, Spiegelman D, Roubenoff R, Gorbach S, Skolnik P. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy. AIDS 1999, 13: 1351-1357. PMID: 10449288, DOI: 10.1097/00002030-199907300-00012.Peer-Reviewed Original ResearchConceptsFat-free massActive antiretroviral therapyHAART useHIV RNAAntiretroviral therapyCohort studyViral burdenKJ/dayHIV-seropositive menCD4 cell countHIV-seropositive personsLog10 copies/Energy expenditureLarge cohort studyIndependent effectsCross-sectional analysisHIV diseaseMedication regimensViral loadCopies/Adjusted REECell countElevated REEViral replicationHAART
1998
The effect of protease inhibitors on weight and body composition in HIV-infected patients
Silva M, Skolnik P, Gorbach S, Spiegelman D, Wilson I, Fernández-DiFranco M, Knox T. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 1998, 12: 1645-1651. PMID: 9764784, DOI: 10.1097/00002030-199813000-00012.Peer-Reviewed Original ResearchConceptsLean body massPI therapyHIV infectionWeight gainViral loadPhysical functioningHealth perceptionBody compositionCurrent health perceptionsActive antiretroviral therapyPI treatmentProtease inhibitor therapyBody mass indexGreater weight gainHuman growth hormoneAntiretroviral therapyHIV cohortBody massInhibitor therapyMass indexOptimal therapyFat massAnabolic stimuliPatientsGrowth hormone